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Aim: A high rate of seropositivity for antibodies against Helicobacter pylori has
been found in many extragastrointestinal diseases. In addition, it has been reported
that the risk of chronic bronchitis may be increased in subjects infected with H.
pylori. This study was designed to determine the H. pylori seroprevalence in patients
with and without chronic bronchitis.
Materials and methods: This study enrolled 68 patients with chronic bronchitis (40
men and 28 women, aged 50.5716.2 years (mean7standard deviation) and 95
control subjects (60 men and 35 women, aged 51.8715.9 years) matched for age
and sex. An enzyme-linked immunosorbent assay immunoglobulin (Ig) G test for
H. pylori diagnosis was performed on all enrolled subjects (those with chronic
bronchitis and controls).
Results: Forty-five of 68 patients with chronic bronchitis (66.1%) and 48 of 95
subjects in the control group (57.7%) tested positive for H. pylori (P ¼ 0.008). Rates
of H. pylori infection are higher in patients with chronic bronchitis than in the
control group.
Conclusion: The main conclusion of this study is that H. pylori infection is
associated with an increased prevalence chronic bronchitis. Further studies should
be planned to understand the potential pathogenetic mechanisms that might
underlie this association.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Worldwide, Helicobacter pylori infection is the
most common chronic bacterial infection of hu-
mans. Seroepidemiologic studies have revealed
that approximately half of all adults in developedElsevier Ltd. All rights reserv
2126868.
om (M. Kanbay).countries and approximately 90% of adults in
developing countries are positive for serum anti-
bodies against H. pylori.1 H. pylori is strongly
associated with type B antral gastritis,2 peptic
ulcer,3 gastric MALT lymphoma,4 and gastric
adenocarcinoma.
H. pylori infection often triggers a marked local
inflammatory response and a chronic systemic
immune response. One hypothesis is that theed.
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pylori infection could induce vascular disorders
through an immune-mediated release of substances
associated with vasospasm or platelet aggregation.
Mediators that have been considered to participate
in the pathogenesis of extradigestive diseases
include interleukin-1 (IL-1), tumor-necrosis factor
alpha (TNF-alpha), interferon gamma (IFN gamma),
leukotriene C4 (LT C4) and platelet-activating
factor (PAF).5,6
A high rate of seropositivity for antibodies
against H. pylori has also been found in many
extragastrointestinal disorders, including coronary
heart disease, rosacea, growth failure in childhood,
active bronchiectasis, and asthma.7–9 It is also well
known that the prevalence of chronic obstructive
pulmonary disease in patients with peptic ulcer is
2–3 times greater than in ulcer-free controls.10 An
epidemiological study in Danish adults also sug-
gested that chronic bronchitis might be more
prevalent in women who were seropositive for Ig
G antibody against H. pylori than in uninfected
subjects.12 However, there are insufficient data
about the prevalence of H. pylori infection in
patients with chronic bronchitis.
This study was designed to determine the
relation between H. pylori infection and chronic
bronchitis. We assessed the rate of seropositivity
for antibodies against H. pylori in a cohort of
subjects with chronic bronchitis and bronchitis-free
control subjects.Table 1 Basic patient and control subject
characteristics.
Patients
(n ¼ 68)
Controls
(n ¼ 95)
P value
Age (years) 50.5 51.8 40.05
Male (%) 63.1 58.8 40.05
Smoking (%) 70.5 55.8 o0.05
Hp
seropositivity
(%)
66.1 50.5 ¼ 0.008Materials and methods
This was a cross-sectional study of patients visiting
the Department of Internal Medicine outpatient
clinic of a university hospital in Turkey between
March 2004 and October 2004 was approved by the
local ethics committee. Sixty-eight consecutive
patients with chronic bronchitis, diagnosed accord-
ing to the American Thoracic Society Guidelines,
were recruited from the outpatient clinic. Briefly,
chronic bronchitis was diagnosed as
’ ’
the presence
of chronic productive cough for 3 months in each of
successive years, in a patient in whom other causes
of chronic cough have been excluded. Exclusion
criteria were (1) an exacerbation of chronic
bronchitis in the preceding month (the exacerba-
tion was defined as
’ ’
increased dyspnea associated
with change in the quality or quantity of sputum,
which led the patient to seek medical attention’’);
(2) prior therapy to eradicate H. pylori infection;
(3) use of acid-suppressive drugs or antibiotics in
the preceding 6 months; and (4) a history ofvagotomy or operations on the upper gastrointest-
inal tract.
Control patients were selected randomly from
our outpatient clinic during the period of study.
Exclusion criteria for controls were (1) a known
history of chronic bronchitis; (2) prior therapy to
eradicate H. pylori; (3) use of acid-suppressive
drugs; and (4) a known history of gastrointestinal
pathology. We selected 95 controls and we matched
them with the patients for age, sex, and socio-
economic status.
An Immulite (chemiluminescent) analyzer (Diag-
nostic Products Corp, Los Angeles, CA, USA) was
used to tested for serum antibodies against H.
pylori infection. This kit has a sensitivity of 97% and
a specificity of 98.8%, according to the manufac-
turer’s guidelines.
Results are presented as mean7SD (standard
deviation). Statistical analysis was carried out using
SPSS software (Statistical Package for the Social
Sciences, version 11.0, SSPS Inc, Chicago, Ill., USA),
and the w2 and Student t-tests. A value for P less
than 0.05 was considered statistically significant.Results
Altogether 68 consecutive subjects with chronic
bronchitis and 95 control subjects were recruited
into this study. The demographic and clinical
details of these subjects are shown in Table 1.
There was no significant difference in age, sex, or
social status between the study and control groups
(P40.05). The majority of patients with bronchitis
were current cigarette smokers (48 patients;
70.5%). Seropositivity for antibodies against H.
pylori in the group of patients with chronic
bronchitis was significantly higher than in the
control group (P ¼ 0.008) (Fig. 1). If we subdivide
the chronic bronchitis and control group as smoker
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Figure 1 Prevalence of seropositivity to H. pylori Ig G antibody in patients with chronic bronchitis and control subjects
without bronchitis (P ¼ 0.008).
Table 2 Seroprevalence of H. pylori according to smoking in chronic bronchitis and control group.
Chronic bronchitis (n ¼ 65) Control group (n ¼ 95)
Hp positivity (%) Hp negativity (%) P Hp positivity (%) Hp negativity (%) P
Smokers 53 47 NS 52 48 NS
Nonsmokers 54 46 NS 54 46 NS
Abreviations: Hp, Helicobacter pylori; NS, non-significant.
Helicobacter pylori seroprevalence in patients with chronic bronchitis 1215and nonsmoker, the seroprevalence of H. pylori was
not statistically significant (P40.05, Table 2).Discussion
Rates of seropositivity for antibodies against
H. pylori have been reported to be higher in
populations of patients with many extradigestive
disorders (including ischemic heart disease, stroke,
and particularly chronic inflammatory diseases such
as rosacea, urticaria, and Henoch-Scho¨nlein pur-
pura) than in the corresponding populations of
persons without these disorders.5–9 Interestingly,
the clinical status of patients with the latter three
conditions has been reported to improve after
eradication of H. pylori.10
The results of this study show that the population
of patients with chronic bronchitis has a signifi-
cantly higher rate of seropositivity for antibodies
against H. pylori than the population of subjects
without chronic bronchitis. Earlier data about the
relationship between H. pylori infection and
chronic bronchitis are limited. Three previous
studies investigated the association between H.pylori seropositivity and chronic bronchitis. Gaselli
et al. found an 81.6% seroprevalence of antibodies
against H. pylori in 60 consecutive patients with
chronic bronchitis and a 57.9% seroprevalence in 69
control subjects (P ¼ 0.008).12 In another study in
Danish women, they found that the presence of
antibodies against H. pylori was associated
with chronic bronchitis.11 In a case-control study,
Roussos et al. found a significant association
between chronic bronchitis and H. pylori.13 While
these studies suggest an association between
chronic bronchitis and H. pylori, the potential
pathogenetic mechanism remains unclear. In fact,
patients with chronic bronchitis receive antibiotics
frequently, and one might expect that the pre-
valence of antibodies against H. pylori would be
lower than in a healthy population. Chronic
bronchitis had been associated with gastroduodenal
ulcer many years before H. pylori infection was
identified as a cause of peptic ulcer. Three
epidemiological studies found that the prevalence
of chronic bronchitis in patients with peptic ulcer
was 2–3 times higher than that in ulcer-free
controls.10,14 Possible confounding factors for this
association are age, sex, smoking, and socioeco-
nomic status.15 It is possible that H. pylori infection
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low-grade inflammatory stimulus. H. pylori is a
gram-negative bacterium and thus contains lipopo-
lysaccharide, a substance that stimulates the
production many cytokines, including interleukin-
1, interleukin-6, and tumor necrosis factor-a.5,6
The eradication of H. pylori leads to normalization
of serum cytokine levels.6 Recent studies showed
that the same cytokines might be released during
the course of chronic bronchitis and exacerbations
of it.12,15 As a result, we emphasize that H. pylori
infection might play a proinflammatory role and co-
trigger chronic bronchitis.
In conclusion, this study showed that H. pylori
seropositivity is high in patients with chronic
bronchitis. Our results must be confirmed by other
studies.
The present study has not focused on the
potential pathogenetic mechanisms underlying the
association between H. pylori infection and chronic
bronchitis. A prospective case control study should
be planned to determine the effects on chronic
bronchitis of eradication therapy for H. pylori and to
understand the possible pathogenetic mechanisms.
Investigation of H. pylori infection especially in
chronic recurrent cases with bronchtis may also help
to understand the relationship and pathogenesis.References
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